Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nab-paclitaxel plus gemcitabine in elderly patients with metastatic pancreatic adenocarcinoma
2014-003596-27Phase 2Completed
- Sponsor
- Asociación de Oncología Médica del Hospital de Cruces
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Asociación de Oncología Médica del Hospital de Cruces. Primary endpoint: 3-month deterioration-free rate. Started Jan 2015; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2014-003596-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003596-27.